PRKD1

Serine/threonine-protein kinase D1 · Q15139 · PRKD1 on Sugi Atlas →

50,578 patent compounds predicted against PRKD1, 33,315 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Ucn-01 (SCHEMBL259162)	1.00	11/20
Staurosporine (SCHEMBL8156)	1.00	9/20
Staurosporine (SCHEMBL8157)	1.00	9/20
Corilagin (SCHEMBL329080)	1.00	8/20
SCHEMBL272173	0.75	7/20
SCHEMBL117745	0.56	7/20
Fasudil (SCHEMBL4674)	1.00	6/20
Fasudil (SCHEMBL317082)	0.98	6/20
SCHEMBL115053	0.56	6/20
SCHEMBL190590	1.00	5/20
SCHEMBL260178	0.81	5/20
Procyanidin B2 (SCHEMBL289082)	0.69	5/20
SCHEMBL190415	0.63	5/20
SCHEMBL78989	0.62	5/20
Phorbol (SCHEMBL72895)	0.62	5/20
SCHEMBL190414	0.62	5/20
Phorbol Myristate Acetate (SCHEMBL115567)	1.00	4/20
SCHEMBL123495	1.00	4/20
SCHEMBL123496	1.00	4/20
SCHEMBL162855	1.00	4/20

Clinical trials — most relevant to PRKD1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Short-Term Metformin Use in Young, Healthy Adults: Impacts on Exercise Capacity	PHASE4	COMPLETED
A Study of the Efficacy and Safety of MT1621 in Thymidine Kinase 2 (TK2) Deficiency (Treatment naïve)	PHASE3	WITHDRAWN
Efficacy and Safety of Endoxifen in Bipolar I Disorder Patients	PHASE3	ACTIVE_NOT_RECRUITING
Evaluate Efficacy and Safety of Endoxifen in Bipolar I Disorder Patients	PHASE3	COMPLETED
Metformin Hydrochloride in Preventing Esophageal Cancer in Patients With Barrett Esophagus	PHASE2	COMPLETED
I/II Phase Study Evaluating M1774 in Combination With Fulvestrant in HR+ and HER2- Advanced Breast Cancers	PHASE1/PHASE2	NOT_YET_RECRUITING
PKC412 and 5-Azacytidine	PHASE1/PHASE2	COMPLETED
Perifosine in Treating Patients With Recurrent, Refractory, Locally Advanced, or Metastatic Breast Cancer	PHASE2	COMPLETED
The Phosphodiesterase 4 Inhibitor Roflumilast as an Adjunct to Antidepressants in Major Depressive Disorder Patients	PHASE1/PHASE2	WITHDRAWN
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer	PHASE2	COMPLETED
Bryostatin 1 in Treating Patients With Metastatic or Recurrent Head and Neck Cancer	PHASE2	COMPLETED
Efficacy of Amlexanox vs. Placebo in Type 2 Diabetic Patients	PHASE2	COMPLETED
A Phase II Study of EVEROLIMUS in Patients With Primary or Relapsed Chondrosarcomas	PHASE2	SUSPENDED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma	PHASE1	COMPLETED
Sirolimus and Gold Sodium Thiomalate in Treating Patients With Advanced Squamous Non-Small Cell Lung Cancer	PHASE1	WITHDRAWN
Auranofin and Sirolimus in Treating Patients With Advanced Solid Tumors or Recurrent Non-Small Cell Lung Cancer	PHASE1	WITHDRAWN
Tabectedin to Treat Children and Adolescents With Cancer	PHASE1	COMPLETED
PKC412, Daunorubicin, and Cytarabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia	PHASE1	COMPLETED
Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors	PHASE1	COMPLETED
Auranofin in Treating Patients With Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer	EARLY_PHASE1	COMPLETED
Pre-Surgical Trial of the Combination of Metformin and Atorvastatin in Newly Diagnosed Operable Breast Cancer	EARLY_PHASE1	COMPLETED
Possible Diagnostic Protein Markers in Schistosoma Related Bladder Diseases.	nan	NOT_YET_RECRUITING
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus	nan	COMPLETED
Defective Atypical Protein Kinase C (PKC) Activation in Diabetes and Metabolic Syndrome	nan	COMPLETED
Longitudinal Natural History Protocol for PRKN- and PINK1-Linked PD	nan	NOT_YET_RECRUITING
Daily Caloric Restriction and Intermittent Fasting in Overweight and Obese Adults With Autosomal Dominant Polycystic Kidney Disease	nan	COMPLETED
Intravenous Terbutaline in Severe Status Asthmaticus	nan	UNKNOWN
Dietary Ketosis: Fatty Acids Activate AMPK Energy Circuits Modulating Global Methylation	nan	COMPLETED
p-AKT Expression on Clinical Outcomes in Malignant Lymphoma	nan	COMPLETED
SMYD3-Driven Metabolic Rewiring in Colorectal Liver Metastases	nan	NOT_YET_RECRUITING

Related proteins — ESM-2 sequence neighbours (a PRKD1 binder may also engage these)

Protein	Name	Similarity
Q9WTQ1	—	1.000	Q9WTQ1 →
Q62101	—	1.000	Q62101 →
Q8K1Y2	—	0.998	Q8K1Y2 →
PRKD3	Serine/threonine-protein kinase D3	0.996	landscape →
Q5XIS9	—	0.995	Q5XIS9 →
Q8BZ03	—	0.993	Q8BZ03 →
PRKD2	Serine/threonine-protein kinase D2	0.990	landscape →
Q8BWW9	—	0.986	Q8BWW9 →
A7MBL8	—	0.985	A7MBL8 →
PKN2	Serine/threonine-protein kinase N2	0.980	landscape →
P00535	—	0.979	P00535 →
MAP3K20	Mitogen-activated protein kinase kinase kinase 20	0.978	landscape →
Q9Z1T4	—	0.977	Q9Z1T4 →
P43249	—	0.977	P43249 →
Q9ESL4	—	0.977	Q9ESL4 →
Q9BYZ6	—	0.976	Q9BYZ6 →
Q6VVX2	—	0.976	Q6VVX2 →
Q5U252	—	0.975	Q5U252 →
Q01826	—	0.975	Q01826 →
Q9R1D7	—	0.975	Q9R1D7 →
A6NI28	—	0.975	A6NI28 →
P28028	—	0.974	P28028 →
Q8BPM2	—	0.974	Q8BPM2 →
O08874	—	0.974	O08874 →
Q3LAC4	—	0.974	Q3LAC4 →
Q7YQL6	—	0.973	Q7YQL6 →
Q6DIX1	—	0.973	Q6DIX1 →
Q5PYH6	—	0.973	Q5PYH6 →
E1C1R4	—	0.973	E1C1R4 →
Q5PYH7	—	0.973	Q5PYH7 →